Report #2826915

Received Feb 18, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: FL
Recovered: Unknown
Vaccinated: —
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	—	—

Symptoms (1)

Cheilitis

Symptom narrative

Rash above lip; This non-serious case was reported by a consumer via call center representative and described the occurrence of rash in a female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (The patient received first dose was on unknown date). On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, 2 months after receiving Shingrix, the patient experienced rash (Verbatim: Rash above lip). The outcome of the rash was unknown. It was unknown if the reporter considered the rash to be related to Shingrix. It was unknown if the company considered the rash to be related to Shingrix. Additional Information: GSK Receipt Date: 13-FEB-2025 The patient had developing a rash above her lip two months after receiving the second dose of Shingrix.